InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Huggy Bear PremiumMember
03/13/24 12:24 PM
profile icon
WV resident Free
03/11/24 2:51 PM
profile icon
LuckyZedd Free
02/18/24 11:52 AM
profile icon
ronrooster Free
02/09/24 6:42 PM
profile icon
archilles Free
02/06/24 1:49 PM
profile icon
archilles Free
02/06/24 1:46 PM
profile icon
Midwestrader Free
01/29/24 7:35 AM
Bearish
Bearish
profile icon
SmellMyFinger Free
01/23/24 11:11 AM
profile icon
Sat Naam Free
01/19/24 5:23 PM
profile icon
oceans11 Free
01/17/24 5:38 PM
profile icon
otcstardmn Free
01/17/24 1:03 PM
profile icon
oceans11 Free
01/16/24 4:09 PM
profile icon
QUEEN2 Free
01/16/24 11:53 AM
profile icon
Fdc4 Free
01/15/24 8:58 AM
profile icon
oceans11 Free
01/09/24 2:32 PM
profile icon
QUEEN2 Free
01/09/24 10:36 AM
profile icon
archilles Free
01/08/24 9:40 PM
profile icon
Jmc1299 Free
12/19/23 6:40 PM
profile icon
SanDiegoAlan Free
12/19/23 4:13 AM
Bearish
Bearish
profile icon
WV resident Free
12/14/23 4:25 PM
profile icon
Sat Naam Free
12/14/23 4:17 PM
profile icon
Sat Naam Free
12/14/23 4:16 PM
profile icon
Sat Naam Free
12/14/23 4:16 PM
profile icon
SidVicious Free
12/14/23 9:33 AM
profile icon
oceans11 Free
12/10/23 3:54 PM
profile icon
SidVicious Free
12/10/23 6:51 AM
Bearish
Bearish
profile icon
QUEEN2 Free
12/08/23 12:43 PM
profile icon
Rider25 Free
12/05/23 5:40 PM
profile icon
Louied91 Free
12/05/23 10:40 AM
Bullish
Bullish
profile icon
SidVicious Free
11/30/23 12:06 AM
Bullish
Bullish
profile icon
robertus Free
11/29/23 12:39 PM
profile icon
Rider25 Free
11/29/23 11:14 AM
profile icon
robertus Free
11/29/23 11:06 AM

Regen BioPharma Inc (RGBP) RSS Feed

Followers
1058
Posters
Posts (Today)
0
Posts (Total)
118342
Created
09/03/14
Type
Free
Moderators Huggy Bear SmellMyFinger

Picture

Regen BioPharma 
 

 0.000x  Ticker Symbol: RGBP 

Barchart



All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html




 
 

Regen BioPharma, Inc. 4700 Spring Street, Suite 304
La Mesa, CA 91942 U.S.A.


Telephone: (619) 702-1404
Fax: (619) 330-2328




Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).






 

Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD
 

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



     

dCellVax 

Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 


     

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia



     

Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia



     
 

 

RGBP Corporate Debt as of September 30, 2022 (latest published financials)

Current News


While the Conventry Debt was paid off (no one has ever contested that), plenty of other debt remains.  The latest Quarterly filing, from November 2022, lists the same list of outstanding debt as the 2nd Quarter filing.

Information on debt still in existance is copied below from the most recent financials signed by the CEO:  https://www.otcmarkets.com/filing/html?id=16204739&guid=dGG-kKAgXc3UQth

As of September  30,2022 the Company has the following Notes  (DEBT) Outstanding

On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.
As of September 30, 2022 $100,000 of the principal amount of the Note remains outstanding.

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

According to RGBP, there is also another Note (debt) issued on the same day, for the same amount (not a duplication)

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is February 24, 2020.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 31, 2020.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

 On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 5, 2020.
As of September  30, 2022 $200,000 of the principal amount of the Note remains outstanding.

On June 26, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $150,000 for consideration consisting of $150,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is June 16, 2020. 
As of September  30, 2022 $150,000 of the principal amount of the Note remains outstanding.

On September 25, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is September 25, 2020.
As of September  30, 2022 $50,000 of the principal amount of the Note remains outstanding.

On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020
As of September  30, 2022, $50,000 of the principal amount of the Note remains outstanding.


On October 16, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 9, 2020. 
As of September  30, 2022 $100,000 of the principal amount of the Note remains outstanding.

On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020.
As of September  30, 2022 $25,000 of the principal amount of the Note remains outstanding.

On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020. 
As of September  30 2022 $25,000 of the principal amount of the Note remains outstanding.

On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020.
As of September 30, 2022 $100,000 of the principal amount of the Note remains outstanding.

On February 28, 2018 (“Issue date”) the Company issued a two Convertible Notes (“Notes”) in the aggregate face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Notes is February 28, 2021. 
As of September  30, 2022 $100,000 of the principal amount of the Notes remains outstanding.

On July 11, 2018 the Company issued a Convertible Note (“Note”) in the face amount of $11,500 to an entity controlled by the Company’s then Chief Financial Officer for consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 4, 2021.
As of September  30, 2022 $11,500 of the principal amount of the Note remains outstanding.

On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date
As of September  30, 2022, 10,000 of the principal amount of the Note remains outstanding.


On July 19, 2019 the Company issued a convertible promissory note in the face amount of $100,000 (“Note”) for consideration consisting of:  $95,000 cash  the payment of $5,000 of legal fees   The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is July 19, 2020

As of September 30, 2022 $1,000 of the principal amount of the Note remains outstanding.


 
On July 19, 2022 Regen Biopharma, Inc. (the “Company”) issued 54,514,492 common shares (“Shares”) to Coventry Enterprises LLC in satisfaction of $180,552 of convertible indebtedness. The principal balance and accrued interest payable remaining on the $1,500,000 promissory note issued to Coventry Enterprises LLC are both $0 as of July 19,2022
 


Lately, there seems to be a lot of gross misunderstanding, with claims that the company has no debt.   This is false, period.  If you see some of the discussion, it only focuses on one debt that was paid.  There is no question that is true, but these same discussions somehow ignore the many other debts.   From the most recent financials filed by the company, this is the list of RGBP's current debt.   
 
 
Share Dilution History
 
 
Date
Outsanding Shares Reason for Issue
12/31/21 4,564,002,832  
3/28/22   4,580,002,832 Debt and Interest
4/7/22 4,736,002,832 Debt and Interest
5/16/22 4,820,002,832 Debt
7/1/22 4,920,002,832 Debt
7/17/22 4,970,002,832 Debt and Interest
8/1/22 5,024,517,324 Debt
8/4/22 5,031,517,324 EXPENSES
     
     



2022 Updates RGBP FAQ

1)  Q: I've seen claims that RGBP has a product or products currently in Phase 1 or Phase 2 testing.  Is this true?
A:  Not a single document singed by the company, nor a single PR released by the company mentions ANY current FDA approved lab doing any Phase 1 or Phase 2 testing for RGBP.   This will be updated, as soon as either of those are provided!   Note, "clearance" is not testing.


Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
RGBP Latest News
  • No Recent News Available for this company!
New Post